No Data
Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) Share Price Could Signal Some Risk
Joinn Laboratories (06127) spent 3.282 million yuan on December 31 to repurchase 0.194 million A-shares.
Joinn Laboratories (06127) announced that it will spend 3.282 million yuan to buy back ...
Joinn Laboratories (06127.HK) spent 1.704 million yuan to repurchase 0.1 million A-shares on December 30.
On December 30, Gelonghui reported that Joinn Laboratories (06127.HK) announced the repurchase of 0.1 million A-shares, costing 1.704 million yuan, on December 30, 2024, with a repurchase price of 16.88-17.11 yuan per share.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Joinn Laboratories (06127.HK) spent 1.714 million yuan to repurchase 0.1 million shares of A-shares on December 23.
On December 23, Gelonghui reported that Joinn Laboratories (06127.HK) announced that on December 23, 2024, it spent 1.714 million yuan to repurchase 0.1 million A-shares, with a repurchase price of 17.1 to 17.18 yuan per share.
Joinn Laboratories will provide Staidson Group with comprehensive pharmaceutical R&D services covering both non-clinical and clinical trial phases.
Joinn Laboratories (06127) announced that on December 20, 2024, the company entered into a framework agreement for Staidson's research and development services for 2025, which will be effective from January 1, 2025, to December 31, 2025. The company is required to provide the Staidson Group with comprehensive pharmaceutical research and development services covering non-clinical and clinical trial phases in accordance with the 2025 Staidson research and development services framework agreement. Due to the long-term cooperation with the Staidson Group, we are able to further expand into the pharmaceutical contract research organization service market and enhance our brand reputation, the Director believes that the 2025 Staidson research and development services framework agreement is in line with the company's strategy.
Earnings Working Against Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) Share Price
No Data
